Liu Fang, Wu Minmin, Wang Jie, Wen Hongyang, An Ran, Cai Haijian, Yu Li, Shen Jilong, Chen Lijian, Du Jian
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
The Research Center for Infectious Diseases, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Front Immunol. 2021 Dec 22;12:755792. doi: 10.3389/fimmu.2021.755792. eCollection 2021.
can infect almost all endotherm organisms including humans and cause life-threatening toxoplasmosis in immunocompromised individuals, which leads to serious public health problems. Developing an excellent vaccine against this disease is impending. In present study, we formulated a cocktail protein vaccine including the TgMIF, TgCDPK3, and Tg14-3-3 proteins, which play critical roles in infection. The recombinant protein vaccines were constructed and assessed by vaccination in mice. We organized the mice in various protein combination groups of vaccines, and all mice were immunized with corresponding proteins at 0, 2, and 4 weeks. The specific protective effects of the vaccines on mice against were analyzed by the mensuration of cytokines, serum antibodies, splenocyte proliferation assay, survival time, and parasite cyst burden of mice after the challenge. The study indicated that mice immunized with all three multicomponent proteins vaccine triggered a strong immune response with highest levels of IFN-γ production and IgG antibody compared with the other two protein combinations and controls. Moreover, there was an increase in IL-4 production and antigen-specific lymphocyte proliferation. The parasite cysts were significantly reduced (resulting in an 82.7% reduction), and survival time was longer in immunized mice with three multicomponent proteins compared with the other groups of mice. The enhanced humoral and cell-mediated immunity indicated that the protein cocktail vaccine containing three antigens provided effective protection for mice. These results indicated that recombinant TgMIF, TgCDPK3, and Tg14-3-3 multicomponent proteins were potential candidates for vaccine against toxoplasmosis.
它几乎可以感染包括人类在内的所有恒温生物,并在免疫功能低下的个体中引发危及生命的弓形虫病,这导致了严重的公共卫生问题。开发一种针对这种疾病的优秀疫苗迫在眉睫。在本研究中,我们制备了一种包含TgMIF、TgCDPK3和Tg14-3-3蛋白的复合蛋白疫苗,这些蛋白在感染过程中发挥关键作用。构建了重组蛋白疫苗并在小鼠中通过接种进行评估。我们将小鼠分为不同的疫苗蛋白组合组,所有小鼠在第0、2和4周用相应的蛋白进行免疫。通过测定细胞因子、血清抗体、脾细胞增殖试验、生存时间以及攻击后小鼠的寄生虫囊肿负荷,分析了疫苗对小鼠的特异性保护作用。研究表明,与其他两种蛋白组合及对照组相比,用所有三种多组分蛋白疫苗免疫的小鼠引发了强烈的免疫反应,产生的IFN-γ水平和IgG抗体最高。此外,IL-4的产生和抗原特异性淋巴细胞增殖有所增加。与其他组小鼠相比,免疫三种多组分蛋白的小鼠体内寄生虫囊肿显著减少(减少了82.7%),生存时间更长。体液免疫和细胞介导免疫的增强表明,包含三种抗原的蛋白复合疫苗为小鼠提供了有效的保护。这些结果表明,重组TgMIF、TgCDPK3和Tg14-3-3多组分蛋白是抗弓形虫病疫苗的潜在候选物。